|
Gene/Clinical
|
Comparison
|
Adjusted DFS
|
|---|
| | |
HR (95% CI)
|
Wald P-value
|
|---|
|
CYP2B6
|
Any variant vs. All WT
|
1.06 (0.77, 1.46)
|
0.72
|
|
CYP2C9
|
Any variant vs. All WT
|
1.11 (0.80, 1.53)
|
0.53
|
|
CYP2D6
|
G/A vs. A/A
|
0.94 (0.46, 1.94)
|
0.87
|
| |
G/G vs. A/A
|
0.99 (0.50, 1.99)
|
0.99
|
|
CYP3A4
|
*1B/*1A vs. *1A/*1A
|
2.79 (1.52, 5.14)
|
0.001
|
| |
*1B/*1B vs *1A/*1A
|
2.67 (0.86, 8.34)
|
0.09
|
|
CYP3A5
|
*3/*1 vs. *1/*1
|
1.18 (0.47, 2.98)
|
0.72
|
| |
*3/*3 vs. *1/*1
|
2.09 (0.79, 5.50)
|
0.14
|
|
CYP3A5
|
*6/*1 vs. *1/*1
|
1.37 (0.39, 4.79)
|
0.62
|
|
GSTM1
|
Null vs. Non-null
|
0.78 (0.57, 1.06)
|
0.12
|
|
GSTT1
|
Null vs. Non-null
|
1.32 (0.86, 2.01)
|
0.21
|
|
GSTP1
|
Any Var vs. All WT
|
0.94 (0.69, 1.28)
|
0.69
|
|
Lymph node
|
Continuous
|
1.02 (1.00, 1.04)
|
0.03
|
|
Tumor size
|
Continuous
|
1.00 (0.97, 1.01)
|
0.46
|
|
Age
|
Continuous
|
0.99 (0.97, 1.01)
|
0.46
|
|
ER
|
Pos vs. Neg
|
--
|
--
|
|
PR
|
Pos vs. Neg
|
1.01 (0.69, 1.50)
|
0.95
|
|
Race
|
Black vs. White
|
1.08 (0.52, 2.25)
|
0.84
|
| |
Other vs. White
|
1.84 (0.91, 3.70)
|
0.09
|
|
Arm
|
CAF+HDC vs. CAF
|
0.66 (0.48, 0.91)
|
0.01
|
- CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: hazard ratio; PR: progesterone receptor
